Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase IV
Recipient : Ali Aminian
Deal Size : Inapplicable
Deal Type : Inapplicable
Bariatric Surgery vs. Semaglutide vs. Tirzepatide
Details : Semaglutide is a Peptide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
January 31, 2025
Lead Product(s) : Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase IV
Recipient : Ali Aminian
Deal Size : Inapplicable
Deal Type : Inapplicable